Oxipurinol - XORTX PharmaAlternative Names: Oxypurinol - XORTX; XORLO; XRx-008
Latest Information Update: 15 Feb 2016
At a glance
- Originator XORTX Pharma
- Class Anti-ischaemics; Antigouts; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Xanthine oxidase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Autosomal dominant polycystic kidney disease
Most Recent Events
- 15 Feb 2016 Clinical trials in Autosomal-dominant polycystic kidney disease in USA (unspecified route)